两部门发布16条举措支持创新药，这些焦点问题与你我息息相关

Core Viewpoint - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, focusing on enhancing R&D support, integrating innovative drugs into insurance directories, and encouraging clinical applications [1][2][3]. Group 1: Support for Innovative Drug R&D - The measures emphasize the organization and implementation of national major science and technology projects for innovative drug R&D, targeting major infectious diseases, chronic diseases, pediatric medications, and rare diseases [1][3]. - The proportion of innovative drugs among new drugs in the medical insurance directory is expected to rise significantly, from 32% in 2019 to 98% by 2024 [2]. Group 2: Integration into Insurance Systems - The policy allows for the inclusion of eligible innovative drugs into the medical insurance directory while maintaining a focus on basic coverage [3][4]. - Commercial health insurance and mutual medical assistance are encouraged to include innovative drugs in their coverage, with a notable growth in the commercial health insurance market, projected to reach 977.3 billion yuan in 2024, an 8.2% increase year-on-year [5][6]. Group 3: Clinical Application and Accessibility - The measures promote the rapid entry of innovative drugs into designated medical institutions, ensuring timely adjustments to drug availability based on clinical needs [4][11]. - Medical institutions are supported in autonomously applying for special cases for innovative drugs that do not fit standard payment models, enhancing the flexibility of drug usage [5][12]. Group 4: Global Market Development - The measures aim to facilitate the global development of innovative drugs, with over 90 overseas licensing transactions completed by Chinese pharmaceutical companies in 2024, totaling over 50 billion USD [9][10]. - The establishment of platforms to assist in expanding overseas markets and providing price support for innovative drugs is a key focus [10].